Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Saturday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their target price on Aethlon Medical from $23.00 to $10.00 and set a buy rating on the stock in a research report on Monday, March 4th.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $1.51 on Friday. Aethlon Medical has a one year low of $1.35 and a one year high of $5.92. The stock has a market capitalization of $3.96 million, a PE ratio of -0.30 and a beta of 1.88. The business’s fifty day moving average is $1.65 and its 200 day moving average is $1.76.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). As a group, sell-side analysts expect that Aethlon Medical will post -4.98 EPS for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.